Meningococcal vaccines: Current state and future outlook
Auteur M. Leca
Auteur C. Bornet
Auteur M. Montana
Auteur C. Curti
Auteur P. Vanelle
Volume 63
Numéro 3
Pages 144-151
Publication Pathologie-Biologie
ISSN 1768-3114
Date Jun 2015
Résumé Neisseria meningitidis infections are a major public health problem worldwide. Although conventional approaches have not led to development of a serogroup B meningococcal vaccine, a new technique based on genome sequencing has created new perspectives. Recently, a universal serogroup B meningococcal vaccine, Bexsero(®), was licensed in Europe, Australia and United States, following several clinical studies demonstrating its immunogenicity and safety. Availability of this vaccine could contribute positively to human health, by significantly reducing the incidence of meningococcal infections. However, unfavorable cost-effectiveness analysis means that routine vaccination is not currently recommended. Another serogroup meningococcal vaccine, Trumemba(®), was also recently licensed in United States. Like any drug, Bexsero(®) and Trumemba(®) will require close observation to assess their impact on meningococcal epidemiology.
Chercher cette référence sur : Google Scholar, Worldcat
doi:10.1016/j.patbio.2015.04.003
Laisser une réponse
Vous devez etre connectez Pour poster un commentaire